R&D
Medical Research and Industry Alliance
To build a robust pharmaceutical industry system with strong core competitiveness and address the issue of dependence on others for key pharmaceutical technologies and core products, since 2017, Wanbangde Pharmaceutical Group has collaborated with experts and professors from over ten leading medical research institutions, including China Pharmaceutical University, Zhejiang University, China Academy of Chinese Medical Sciences, Second Military Medical University, Beijing Anzhen Hospital, West China Hospital of Sichuan University, and the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine. This initiative is spearheaded by Academician Wang Guangji, who has established the consortium.China's first collaborative alliance integrating medicine, research, and industry for pharmaceutical products—the Ginkgo Leaf Droplet Pill Innovation Alliance.Focusing on in-depth research of the company's flagship product, Ginkgo Biloba Dropping Pills, and achieving remarkable results: a total of scientific papers published along with their impact factors.21Article; Granted a patent11Item; Included14Clinical guidelines, expert consensus documents, and the "Interpretation of Clinical Pathways" jointly developed under the guidance of the National Health Commission—among others; the product has received prestigious awards.12Item.
China Pharmaceutical UniversityJoint Research and Development Center
Collaboration Time
September 2015 – Present
Project Details
February 2017
Sign a co-construction agreement"China Pharmaceutical University - Wanbangde Drug Joint Research and Development Center"The research center for agreements has secured total funding exceeding 10 million over the past five years.
2022
Planning to sign the second long-term cooperation agreement
● Led by Academician Guangji Wang from China Pharmaceutical University, with Vice President Haiping Hao serving as the Secretary-General, the nation's first collaborative innovation initiative involving medical research, industry, and academia in pharmaceutical product development has been established.United
AllianceGinkgo Leaf Droplet Pill Medical-Research-Enterprise Collaborative Innovation Alliance"Setting the direction for R&D of the company's core product lines."
● The studies titled "Mechanism of Action of Ginkgo Leaf Dropping Pills in Preventing and Treating Ischemic Stroke" and "Interaction Between Ginkgo Leaf Dropping Pills and Statin Drugs" have been signed."Research on the Effects and Mechanisms of Ginkgo Leaf Droplets and Other Compounds on PCSK9 Expression in Vivo and in Vitro," and "Elucidation of the Key Active Component Groups in Ginkgo Leaf Droplets and Their Quality Standards.""Research on Upgrading Quality Standards," "Study on Copper Leaf Extract as an EU-Registered Quality Standard," and "Huperzine A Injection for Preventing and Treating Cognitive Impairments Associated with Traumatic Brain Injury.""Research on the PK-PD Integration of Barriers," along with other contract systems, is being used to conduct secondary development studies on products such as Ginkgo Leaf Dropping Pills and Huperzine A Injection.
Achieve results
CultivateMore than 10Master's, PhD, Postdoctoral
1
SCI Publication
1
Chinese Core
Publish
1
Apply for a
patent
Zhejiang UniversityJointly Establishing a Research Center
Collaboration Time
July 2015 – Present
Project Details
November 2016
Sign a co-construction agreement"Zhejiang University - Wanbangde Joint Research Center for Modernization of Traditional Chinese Medicine"Cooperation Agreement: The research center has secured total funding exceeding 10 million yuan over the past five years—already surpassing the target.
2017
Established jointly with the School of Pharmaceutical Sciences at Zhejiang University"Zhejiang University School of Pharmaceutical Sciences – Wanbangde Pharmaceutical Group Co., Ltd. Professional Degree Graduate Practice Base"
December 2018 – December 2019
Wanbande, as the sponsor, is funding one postdoctoral researcher from Zhejiang University to pursue advanced studies at the University of Geneva.
December 2021
Sign a co-construction agreement"Zhejiang University School of Pharmaceutical Sciences – Wanbangde Joint Research Center"Cooperation Agreement: The research center will have a total funding of over 6 million within three years.
Achieve results
CultivateMore than 10Master's, PhD, Postdoctoral
7 articlesSCI published1 articleChinese Core Publication2 itemsPatent successfully introduced
Led by Wanbande Pharmaceutical Group, with a professor from Zhejiang University serving as the project leader.Approved for the 2018 Zhejiang Provincial Key R&D ProgramCurrently, the project has completed its final acceptance review and is now planned to be nominated for a provincial or ministerial-level award.
University of SydneyScholarship-funded doctoral programs for Chinese students
Collaboration Time
August 2018 – Present
Project Details
The agreement stipulates that Wanbangde Pharmaceutical Group will fund scholarships through the "Wanbangde-University of Sydney Postgraduate Scholarship Program," providing financial support to University of Sydney-based research master’s or doctoral students. These scholarships will enable them to conduct studies and evaluate the effects of products like Ginkgo Biloba Dropping Pills on retinal degenerative diseases.
August 2018
Signing the first scholarship agreement (January 1, 2019 – December 31, 2019) and the strategic cooperation agreement
March 2020
Signing the second scholarship agreement (2020.1.1–2021.12.31)
January 2022
Signing the third scholarship agreement (March 1, 2022 – February 28, 2025)
Achieve results
1
Supervising doctoral students
3
Published in SCI
1
Accepted to SCI